{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021648","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.192454+00:00","generated_at":"2026-06-02T09:15:17.665994+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ChromaDex Q1 net sales $22.2M, net loss narrows to $0.5M; reiterates 16%+ FY growth","bullets":["Net sales $22.2M (-2% YoY); Tru Niagen sales $17.4M. Gross margin 60.7% (+80 bps).","Net loss $0.5M ($0.01 loss per share), improved from $1.9M loss in Q1 2023.","Adjusted EBITDA positive $0.7M vs -$0.1M prior year; cash $27.6M, no debt.","Full-year 2024 outlook reiterated: net sales growth of at least 16%.","Tru Niagen expanded to 700 Vitamin Shoppe stores and 400 Sprouts Farmers Market locations."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021648","json":"https://secwatch.observer/filing/0001628280-24-021648.json","markdown":"https://secwatch.observer/filing/0001628280-24-021648.md","text":"https://secwatch.observer/filing/0001628280-24-021648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024021648/0001628280-24-021648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024021648/cdxc-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:15:17.665994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b879660f94e7f07e0a4d18a2369d3b575dba14cf","claim":"Niagen Bioscience, Inc. reported first quarter of 2024 results: revenue $22.2 million, net income $0.5 million, EPS $(0.01) per share. Guidance reaffirmed.","evidence_excerpt":"ChromaDex Corporation Reports First Quarter 2024 Financial Results Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024021648/0001628280-24-021648-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"$22.2 million"},{"label":"Net income","value":"$0.5 million"},{"label":"EPS","value":"$(0.01) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}